When self-defense becomes self-harm
The Immune system, protects the human body from a range of adverse agents – infectious or non-infectious but is also equipped with a sophisticated range of options to prevent or obstruct injury to its own tissues by recognizing self as opposed to non-self. The failure of one or more mechanisms of self-tolerance results in autoimmunity (AI): a relentless targeting of tissues of single or multiple organ systems, with a higher risk in females, summarized in the poem below. Enablers of autoimmunity are genetic predisposition, complemented by environmental triggers. T-cell or B-cell dominant pathways (or both), execute the damage. A spectrum of clinical entities result: one of the best examples, suspected clinically and confirmed by laboratory tests, is Systemic lupus erythematosus (SLE), the prototype of a multi-system connective tissue disorder or collagen vascular disorder as this group of diseases are often referred to. Despite advances in understanding the cellular and signaling mechanisms, treatment options are at best disease-modifying and cures are not yet visible on the therapeutic horizon, attesting to the complexity of disease pathways. On the other hand, useful applications exist in the realm of oncologic practice where interrupting self-tolerance has been used as a precision medicine tool to treat tumors as a form of targeted immunotherapy.
Insights and Impact
- Auto-immunity, signifying failure of self-recognition which is an innate mechanism of self-protection, includes an expanding list of clinical entities with emergence of interdisciplinary Autoimmunology as a science
- In SLE, the best-established multi-system disorder of this class of diseases, both clinical criteria and a host of specific antibodies serve to establish diagnosis with accuracy
- It is noteworthy that in contemporary, sub-specialty practice of Medicine, patients with SLE and other multi-system AI disorders may clinically present in diverse ways. A high degree of clinical suspicion and collaborative referral across specialty lines is instrumental in establishing the diagnosis and offering comprehensive, multi-disciplinary management, for the best outcome
- Single-organ diseases are easier to establish, are less morbid, yet still limited in the possibility of curative efforts
- Current medical therapy, focused on interrupting autoreactivity and its downstream effects, is evolving, as attempts to interrupt the pro-inflammatory destructive signaling pathways lend themselves to pharmacologic research
- Once diagnosed, the lifelong nature of the disease – with exacerbations, remissions and relapses – is a lifestyle modifying, morbid experience for the patient and a challenge to management by multi-disciplinary teams
- Rehabilitative and mental health support for the patient and caregivers is an important pillar of management to ensure compliance with treatment options and to cope with disease outcomes
Rhythm ’n rhyme
Turning turtle: the enemy within
Central and peripheral self-tolerance are designed to protect
So that immune mechanisms will only, to non-self, deflect;
During central maturation: deletion eliminates, editing inactivates T & B self-reacting cells
Suppression, inactivation, FAS-FAS-L triggered-apoptosis in the periphery, toll the last bell;
Anergy is the outcome, when regulatory T cells and APC’s shake hands
CTLA-4 and PD-1 are co-inhibitory receptors, that with ligands form a band;
Testis, brain and eye tissues are from immunity, hidden in plain sight
Injury, inflammation, infection (triple-I) can unveil antigens, then Immunity will bite!
Multiple susceptibility genes induce autoimmunity, HLA alleles, come into play
Strong evidence for Ankylosing spondylitis; in SLE, rheumatoid arthritis, the links are grey;
The evidence, for non-MHC gene polymorphisms in AI, is gathering apace
Type 1 diabetes, Crohn’s, Multiple sclerosis may be the resultant clinical face;
Environmental trigger-trio - triple-I - through co-stimulation and molecular mimicry work
Streptococcus-myocardium share antigens in Rheumatic fever, immunity response doesn’t shirk;
EBV and HIV lurk in cells, polyclonal B cell activation the result
Damaged cells bare neoantigens-stimulate cytokines, T-cells respond with tissue insult;
Whether T- or B-cell-mediated/ hybrid, autoimmune diseases’ pathogenesis define
Antibodies in Systemic lupus erythematosus, in Scleroderma T-cell dominance align;
Women are unfortunately favored, relapse and remissions the clinical course
Organ-specific in Myasthenia, Grave’s disease; lung-kidney BM’s in Goodpasture express remorse;
Specific antibodies support classification criteria, biopsies are needed in some
Imaging maps multisystem involvement, follow-ups required till-kingdom-come;
DMRDs, steroids, NSAID’s and the like, reduce the pathological toll
Physician-patient patience the need of the hour: compliance-review underpin control;
Deep Dive
A. Autoimmunity – pathways and proposed panaceas
Acknowledgement of image –https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1626082
Q. Review the target pathways established therapies adopt in the management of autoimmune diseases
B. Systemic lupus erythematosus – prototype of autoimmunity
Acknowledgement – placed on Image
DIY.
- List all the clinical specialties to whom a patient of SLE is likely to present.
- Select the top 5 from your list with whom the majority of SLE patients seek consultation in clinical practice.
Read on:
- Aster, J. C. Robbins, Cotran & Kumar Pathologic Basis of Disease, 11th Edition. Elsevier – Evolve; 2025-05-09. Retrieved from vbk://97804432839322025-05-09.
- https://www.osmosis.org/learn/Systemic_lupus_erythematosus:_Clinical_sciences
Leave a Reply